Login to Your Account

Earnings Roundup

Friday, May 3, 2013
• Incyte Corp., of Wilmington, Del., posted net product revenues from sales of myelofibrosis drug Jakafi (ruxolitinib) totaling $48.3 million for the first quarter, with product royalties from sales of the drug, marketed as Jakavi outside the U.S. by partner Novartis AG, of Basel, Switzerland, totaling $5.9 million.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription